Unknown

Dataset Information

0

IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer.


ABSTRACT: As regulatory T cell (Treg) adoptive therapy continues to develop clinically, there is a need to determine which immunomodulatory agents pair most compatibly with Tregs to enable persistence and stabilize suppressor function. Prior work has shown that mechanistic target of rapamycin inhibition can increase the stability of thymic Tregs. In this study, we investigated the transcriptomic signatures of ex vivo-expanded Tregs after adoptive transfer in the setting of clinically relevant immunosuppression using a nonhuman primate (NHP) model as a prelude to future transplant studies. Here, we found that adding interleukin-2 (IL-2) to rapamycin in vivo supported a logarithmic increase in the half-life of adoptively transferred carboxyfluorescein diacetate succinimidyl ester-labeled, autologous NHP Tregs, effectively doubling the number of cells in the peripheral blood Treg compartment compared with Treg infusion when rapamycin was given alone. Using single-cell transcriptomics, we found that transferred ex vivo-expanded Tregs initially exhibit a gene expression signature consistent with an activated state. Moreover, those cells with the highest levels of activation also expressed genes associated with p53-mediated apoptosis. In contrast, transferred Tregs interrogated at day +20 posttransfer demonstrated a gene signature more similar to published profiles of resting Tregs. Together, these preclinical data further support combining IL-2 and rapamycin in vivo as adjunctive therapy for ex vivo-expanded adoptively transferred Tregs and suggest that the activation status of ex vivo-expanded Tregs is critical to their persistence.

SUBMITTER: Furlan SN 

PROVIDER: S-EPMC7189290 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

IL-2 enhances ex vivo-expanded regulatory T-cell persistence after adoptive transfer.

Furlan Scott N SN   Singh Karnail K   Lopez Christina C   Tkachev Victor V   Hunt Daniel Joel DJ   Hibbard James J   Betz Kayla M KM   Blazar Bruce R BR   Trapnell Cole C   Kean Leslie S LS  

Blood advances 20200401 8


As regulatory T cell (Treg) adoptive therapy continues to develop clinically, there is a need to determine which immunomodulatory agents pair most compatibly with Tregs to enable persistence and stabilize suppressor function. Prior work has shown that mechanistic target of rapamycin inhibition can increase the stability of thymic Tregs. In this study, we investigated the transcriptomic signatures of ex vivo-expanded Tregs after adoptive transfer in the setting of clinically relevant immunosuppre  ...[more]

Similar Datasets

| S-EPMC2696596 | biostudies-literature
| S-EPMC5016253 | biostudies-literature
2023-04-14 | GSE229607 | GEO
| S-EPMC8250091 | biostudies-literature
| S-EPMC2704307 | biostudies-literature
| S-EPMC4214360 | biostudies-literature
| S-EPMC2929438 | biostudies-literature
| S-EPMC6682349 | biostudies-literature
| S-EPMC4213815 | biostudies-literature
| S-EPMC5004946 | biostudies-literature